Expression of Glut-1 in Normal Endometrium and Endometrial Lesions: Analysis of 336 Cases
Language English Country United States Media print-electronic
Document type Journal Article
- Keywords
- Glut-1, clear cell carcinoma, endometrioid carcinoma, endometrium, hyperplasia, immunohistochemistry, serous carcinoma,
- MeSH
- Adenocarcinoma, Clear Cell diagnosis pathology MeSH
- Biopsy MeSH
- Diagnosis, Differential MeSH
- Adult MeSH
- Endometrium pathology MeSH
- Carcinoma, Endometrioid diagnosis pathology MeSH
- Endometrial Hyperplasia diagnosis pathology MeSH
- Immunohistochemistry MeSH
- Middle Aged MeSH
- Humans MeSH
- Young Adult MeSH
- Biomarkers, Tumor metabolism MeSH
- Endometrial Neoplasms diagnosis pathology MeSH
- Polyps diagnosis pathology MeSH
- Precancerous Conditions diagnosis pathology MeSH
- Glucose Transporter Type 1 metabolism MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Neoplasm Staging MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Young Adult MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Names of Substances
- Biomarkers, Tumor MeSH
- Glucose Transporter Type 1 MeSH
- SLC2A1 protein, human MeSH Browser
BACKGROUND: Glucose transporter-1 (Glut-1) is a membrane glycoprotein that is, together with other glucose transporters, responsible for the regulation of glucose uptake. An increased expression of this protein seems to be a general feature of several malignant tumors that are able to reprogram their metabolism and switch from oxidative phosphorylation to aerobic glycolysis. METHODS: We performed comprehensive immunohistochemical analysis of Glut-1 expression in 336 endometrial samples, including tumors, nontumor lesions, and normal tissues. RESULTS: Expression of Glut-1 was found in 87% of endometrioid carcinomas (160/184 cases), 100% of serous carcinomas (29/29 cases), 100% of clear cell carcinomas (17/17 cases), 50% of polyps with atypical hyperplasia (8/16 cases), 12.5% of polyps with non-atypical hyperplasia (3/24 cases), 77% of hyperplasias with atypias (10/13 cases), 9% of hyperplasias without atypias (1/11 cases), 87% of secretory endometrium samples (13/15 cases), and in none of the nonsecretory endometrium samples (0/27 cases). In endometrioid carcinomas, Glut-1 was expressed in a marked geographical pattern. In nontumor lesions, its expression was more common in atypical hyperplasia and polyps with atypical hyperplasia compared with polyps with non-atypical hyperplasia and hyperplasias without atypia ( P = .00032). CONCLUSION: Our study confirms the high expression of Glut-1 not only in endometrioid carcinomas but also in other carcinomas of endometrium including clear cell and serous types. Glut-1 expression can be used as a surrogate marker in differential diagnosis between hyperplasia with and without atypia. Because of common Glut-1 expression in malignant tumors, therapeutic strategies influencing this protein or its signaling pathways can be beneficial.
References provided by Crossref.org
